Dexmedetomidine to facilitate drug withdrawal

  The alpha2-adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects

  Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study.

  Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care.

  Respiratory effects of dexmedetomidine in the surgical patient requiring intensive care.

  Initial experience with dexmedetomidine in pediatric aged patients.

  Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit.

  Comparison between dexmedetomidine and propofol for sedation in the intensive care unit: patient and clinician perceptions.

  Bispectral index-guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study

  Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in post-operative patients needing sedation in the intensive care unit.

  Dexmedetomidine attenuates sympathoadrenal responses to tracheal intubation and reduces the need for thiopentone and peroperative fentanyl.

  Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.

  Preliminary UK experience of dexmedetomidine, a novel agent for postoperative sedation in the intensive care unit.

    Back to Summaries List